| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition
Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash runway into the second half of 2028 |
| 22 Oct 2026 |
8-K: Other Events
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency |
| 05 Oct 2026 |
8-K: Other Events
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background |
| 19 Aug 2026 |
8-K: Other Events
On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleot... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 10, 2026, or the Annual Meeting. |
| 19 May 2026 |
8-K: Other Events
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing ... |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This Subscription Agreement (this “Agreement”) is made and entered into as of March 9, 2026 (the “Effective Date”) by and among Korro Bio, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature p... |
| 27 Jan 2026 |
8-K: Other Events
KRRO-121: A Potential First-in-Class Treatment for Ammonia Control January 27th, 2026 Exhibit 99.1 |
| 15 Jan 2026 |
8-K: Other Events
Forward-Looking Statement and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amend... |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This Amended and Restated Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Jeffrey Cerio (the “Ex... |
| 12 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients |
| 08 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This Separation Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Vineet Agarwal (the “Executive”). The Compa... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 |
| 11 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The following is a summary of the matters voted on at the 2025 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 11, 2025, or the Annual Meeting. |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 |
| 27 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 18 Mar 2025 |
8-K: Results of Operations and Financial Condition
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 |
Loading...